C hronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular disease (CVD). [1] [2] [3] [4] [5] [6] [7] [8] While some of the concurrence of lung and heart disease may be attributable to common risk factors such as cigarette smoking and age, CVD burden is greater in people with COPD than the general population independent of these shared risk factors. 4, 9 Furthermore, this association does not appear to be simply driven by the common risk factor of cigarette smoking. Even in the absence of lung disease (including in nonsmokers), reduced lung function is associated with risk of future CVD. We have previously shown the association between lung function measured in early adulthood and the development of hypertension later in life. 10 In the Framingham Heart Study, forced vital capacity (FVC) at a mean age of 40 to 45 years was associated with risk of subsequent CVD. 11 This age range, however, is older than when most people attain peak lung function (typically around age 25-35 years) 12 and at an age when lung disease starts to become clinically apparent. 13, 14 Most reports of associations between chronic respiratory disease and CVD have been cross-sectional studies of individuals with either established lung disease or in older populations at risk for lung disease. 5, 6, 8, 15, 16 However, it was recently reported in a study of 3 independent cohorts that an abnormal (<80% of the predicted value) forced expiratory volume in 1 second (FEV 1 ) was associated with accelerated development of respiratory, cardiovascular, and metabolic comorbidities. 17 In a prior analysis, it was also noted that an abnormal FEV 1 early in life is associated with increased risk of future COPD independent of rate of decline, 18 suggesting that peak lung health in young adulthood is an important risk factor for a variety of future health consequences. These findings replicate and reinforce those previously reported in the CARDIA (Coronary Artery Risk Development in Young Adults) study of young adults aged 18 to 30 years recruited in 1985, 10, [19] [20] [21] [22] [23] which was included in the 3 cohort study described above, but only included an intermediate-term follow-up interval of 20 years (to a mean age of 45 years). 17 Although of interest, testing the association between only those with abnormal lung function (<80% predicted) and future comorbid conditions does not acknowledge the full potential impact of measurements of peak lung function. The association of overall respiratory health in young adulthood and future comorbid conditions likely operates on a continuum in which lung function ranging from ideal to abnormal is associated with overall health outcomes later in life. Given the considerable interest in both the respiratory and cardiovascular communities in identifying distinct patient phenotypes (in COPD for example, recognizing that people with lower peak lung function in early adulthood who have COPD are different from those with accelerated decline), expanding our understanding of how peak lung function is associated with different phenotypic expressions of CVD is critical to more precisely understand the concurrent evolution of heart and lung conditions. 24 In the present article, we utilized the complete CARDIA study events data to test the association between lung health in young adulthood (mean age 25 years, range 18-30 years) and cardiovascular events (including coronary heart disease [CHD] events, stroke, and heart failure) over nearly 30 years of followup. We hypothesized that lung health in young adulthood is an independent risk factor for future cardiovascular events and subclinical atherosclerosis.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The CARDIA study has a formal centralized process for requesting data and study materials, which can be accessed through its website: www.cardia.dopm.uab.edu.
Study Design and Sample
CARDIA is a prospective cohort study of the evolution of CVD risk factors in young adults. 25 What Are the Clinical Implications?
• This association, which appears to be independent of atherosclerotic heart disease, adds to the growing body of evidence exploring the importance of peak lung health attained in young adulthood on the coevolution of heart and lung disease across the adult lifespan.
spirometry procedures as recommended by the American Thoracic Society were followed at each examination in which lung function was measured. 26, 27 Lung function measurements including FVC (the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible), FEV 1 (the volume of air exhaled in the first second of a forced exhalation maneuver), and FEV 1 /FVC ratio were calculated. The FVC can serve as a marker of lung health that encompasses total lung volume as well as respiratory muscle strength. The FEV 1 can serve as a marker of airway disease in the lung. The FEV 1 /FVC ratio is the diagnostic marker used to define obstructive airway disease.
CVD Events
Definitions of all-cause mortality and cardiovascular events have been previously described. [28] [29] [30] [31] [32] [33] [34] At the time of this analysis, there were 233 CVD events recorded over %29 years of follow-up in the analytic cohort of 4761 participants. Of the 5115 participants originally enrolled, 354 were excluded from the analysis to arrive at the analytic cohort of 4761 participants; 1 patient withdrew consent, 254 patients were missing baseline pulmonary function data, and 99 patients were missing baseline covariate data ( Figure S1 ).
We further categorized the first cardiovascular events into 3 mutually exclusive groups: cerebrovascular disease events (fatal and nonfatal stroke, transient ischemic attacks, and carotid artery disease) (n=57); CHD events (nonmyocardial infarction acute coronary syndrome, myocardial infarction, and death caused by atherosclerotic CHD) (n=112); and heart failure events (congestive heart failure, and death caused by nonatherosclerotic cardiac disease) (n=56). Because peripheral arterial disease events have a pathogenesis not consistent with the 3 categories we defined, event times for 8 participants with peripheral arterial disease were treated as censored. Furthermore, 8 participants had multimorbid first CVD events on the same day, guidelines laid out by the CARDIA study for addressing these are as follows: myocardial infarction and nonmyocardial infarction acute coronary syndrome take precedence over both congestive heart failure and stroke, transient ischemic attack, or carotid artery disease as first event. Stroke, transient ischemic attack, or carotid artery disease take precedence over congestive heart failure as first event. Any event takes precedence over death (with the idea being that death follows other events as the proximate cause of death).
Participants free of CVD events were censored at the date of non-CVD death (n=268), last contact (n=4260), or August 31, 2015, whichever occurred first.
Coronary Artery Calcuim Score
The Agatson coronary artery calcium (CAC) score was measured in 2978 of the 4761 participants with a multidetector computed tomography system in accordance with standard protocols at year 25 examination, as previously described. 35 
Carotid Intima-Media Thickness
Carotid intima-media thickness (CIMT) was measured in 3046 of the 4761 patients at year 20 examination in the CARDIA study with high-resolution B-mode ultrasound in accordance with standard procedures. 36, 37 Measurement of maximum average common CIMT and average maximum internal CIMT were included in the analysis.
Statistical Analysis
Age-, race-, and sex-adjusted rates of CVD events per 1000 patient-years were computed across quintiles of FEV 1 , FVC, and FEV 1 /FVC ratio. Cox proportional hazards regression analysis was used to assess the association of baseline lung function measures and incident CVD events (sample size: 4761, events: 233). Covariates in the analysis included baseline age, race-sex group (model 1), baseline body mass index (BMI), smoking status (current, former, or never), and highest education level (model 2). In a third model, designed to assess the association between lung function and cardiovascular events independent of classic CVD risk factors, diabetes mellitus (defined as fasting glucose ≥126 mg/dL or use of diabetic medication), systolic blood pressure (BP), use of antihypertensive medications, total cholesterol, and highdensity lipoprotein cholesterol (note that no participants were taking cholesterol medication at the baseline examination) were added as covariates. Similar analysis was completed using lung function measurements at the year 10 (sample size: 3627, events: 186) and year 20 (sample size: 3295, events: 102) examinations as the main predictor variables. Linear regression was used to test the association between baseline lung function and CIMT at year 20. Covariates included in these analyses included age, race-sex group, highest education level, diabetes mellitus, BMI, total cholesterol, highdensity lipoprotein cholesterol, systolic BP, BP medication use, and smoking status (current, former, or never). The prevalence of CAC >0 Agatston units and >100 Agatston units adjusted for age, race, and sex was computed across quintiles of lung function including FEV 1 , FVC, and FEV 1 /FVC ratio. Logistic regression was used to model the association of baseline lung function and CAC >0 and CAC >100, with inclusion of the same covariates as in the CIMT models.
Logistic regression was used to test the associations of lung function measured at the year 10 examination with incident cardiovascular risk factors (defined as present at year 20 and not present at year 10) including hypertension (defined as a systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or use of BP medications), hypercholesterolemia (defined as total cholesterol ≥200 mg/dL or use of cholesterollowering medications), and diabetes mellitus (fasting blood glucose >126 mg/dL or use of diabetic medications). Covariates in this analysis included age, race-sex groups, BMI at year 10, change in BMI defined as year 20 minus year 10, and smoking status (current, former, or never) at year 10.
Results
A total of 4761 participants who had lung function testing and were not missing baseline covariates at the baseline examination were included in the analysis. Baseline characteristics of the sample, stratified by presence or absence of cardiovascular events, are shown in Table 1 . CVD event rates per 1000 patientyears adjusted for age, sex, and race across quintiles of lung function are shown in Figure S2A through S2C. In the cohort as a whole, the mean age was 24.9AE3.6 years, over half (55.7%) reported being never-smokers, and lung function was generally normal (FEV 1 97.8AE11.8% predicted) with only 166 (3.49%) having an FEV 1 /FVC ratio of <70. The incidence of obstructive airway disease, defined as an FEV 1 /FVC ratio of <70, remained low at both the year 10 (n=227, 6.26%) and year 20 (n=281, 8.53%) examinations.
Association Between Baseline Lung Function and Cardiovascular Events
Lower baseline FEV 1 and FVC were both associated with greater risk of cardiovascular events (Table 2 ). These associations between lung function and cardiovascular events were similar in models adjusted for traditional cardiovascular risk factors including BP, total cholesterol, and diabetes mellitus determined at the same time as lung function. The hazard ratio per each À10-unit decrement in FEV 1 Figure A,D) .
The fully adjusted models were repeated using year 10 (mean age 35 years, range [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] In secondary analysis of specific adjudicated cardiovascular event subtypes, significant associations were found between both baseline FEV 1 and FVC with cerebrovascular events. On the other hand, FVC but not FEV 1 was associated with risk of heart failure events and neither FEV 1 or FVC were significantly associated with CAD events (Table 3) .
Association Between Baseline Lung Function and Subclinical Atherosclerosis
Given prior literature showing an association between COPD and CHD 38 we assessed the association between baseline lung function and the presence of both common CIMT and maximum internal CIMT at year 20 as well as CAC at year 25. We found that baseline FEV 1 and FEV 1 /FVC ratio but not FVC were inversely associated with mean maximal common CIMT.
No association was noted between any baseline lung function measurements and mean maximal internal CIMT (Table 4) . We also found no association between baseline FEV 1 , FVC, or FEV 1 /FVC ratio with either presence of CAC at year 25 nor with presence of CAC score >100 at year 25 after adjustment for covariates including BMI, diabetes mellitus, BP, cholesterol, and smoking status (Table 4) , The prevalence of CAC >0 Agatston units and CAC >100 Agatston units across quintiles of baseline lung function is shown in Figure S2D through S2F.
Association Between Year 10 Lung Function and Incident Cardiovascular Risk Factors
To explore why baseline and year 10 lung function were both associated with future cardiovascular events but year 20 was not, we tested whether year 10 lung function was associated with the development of CVD risk factors at year 20. We found that year 10 FEV 1 (odds ratio, 1.09; 95% CI, 1.00- (Table S1 ).
Discussion
In this community-based study of generally healthy young adults followed for nearly 30 years, we found that baseline lung function measured at a mean age of 25 years (range 18-30 years) is associated with greater risk of future CVD events over the subsequent 29 years. This association was independent of sex, race, smoking, BMI, total cholesterol, BP, and diabetes mellitus. These findings add to a growing body of evidence that peak lung function in young adulthood has important implications for future respiratory and overall health. The implication of these findings is that lung function testing in early adulthood may provide an early window into cardiovascular health at a time when the evolution of potential heart and lung disease is in its beginning stages.
Established lung diseases such as COPD are associated with CVD and poor health outcomes. 3 Even among patients who do not meet spirometric criteria for COPD, reduced lung function (defined as the lowest quintile of FEV 1 ) is associated with cardiovascular death. 5 Furthermore, low lung function and obstructive lung physiology have been linked with greater risk of incident heart failure. 39, 40 Most of these reports focus on measurements of lung function in middle age. Little is known about the association between lung function measured around the time it peaks in young adulthood and future cardiovascular outcomes. We have previously observed in the CARDIA study an association between FVC decline and incident hypertension. 10 Furthermore, we have also described in this cohort that patterns of loss of lung health are associated with distinct echocardiographic phenotypes in middle age. 41 The results of both of these studies are notable in that the majority of participants still had lung function that would typically be considered in the normal range (ie, >80% of their predicted value for FEV 1 or FVC). This highlights the importance of evaluating lung function in young adulthood as a continuum (rather than using cutoff levels for disease) as overall lung health is associated with cardiovascular risk even before the onset of clinically overt lung disease. In the current analysis, we show that measurements of lung function occurring as early as in an individual's 20s are associated with future CVD events. This finding mirrors recent work showing that abnormal lung function in early adulthood is an important risk factor for the development of future COPD.
19,42
The aggregate of these findings highlights the importance of the measurement of lung function in early adulthood around the time lung function peaks not only as an important predictor of the development of future lung disease but as a key parameter to understand the concurrent evolution of lung and heart disease.
The mechanism of association between lung function in young adults and CVD events is unknown. Given the known association between lung disease and CHD events later in life, 4, 8 one striking finding from our study was the lack of association between baseline lung function and indicators of atherosclerotic disease. 43, 44 We found that baseline lung function was not associated with CHD events such as myocardial infarction and acute coronary syndrome in the CARDIA study. Furthermore, year 10 lung function was not associated with year 20 elevated total cholesterol levels nor did we see any association between baseline lung function and the presence of future coronary artery calcified plaque. When we examined the association between lung health and CIMT measurements, no association was noted with measurement of internal carotid artery intima-media thickness, which is associated with vascular plaque formation and predictive of CHD events. 37, 45, 46 These findings suggest that the hypothesis that common exposures such as tobacco smoke, likely by triggering inflammatory pathways, leads to both lung injury with subsequent lung function decline and eventually lung disease and activation of atherosclerotic pathways leading to the development of CHD may not tell the whole story. 47 Our findings suggest that in addition to exposure-driven pathways in the development of COPD and CHD, peak lung health attained in young adulthood is predictive of unique mechanisms that contribute to the coevolution of heart and lung disease. We did find that baseline lung health was associated with both cerebrovascular events and heart failure events. Furthermore, year 10 FEV 1 was predictive of both elevated year 20 BP and common carotid artery intima-media thickness. As opposed to internal carotid artery intima-media thickness, common carotid artery intima-media thickness has been associated with increased sheer stress, hypertension, cerebrovascular events, and pathologically more diffuse vascular changes rather than focal plaque formation. 37, 48, 49 Furthermore, we noted an association between year 10 lung function and incident diabetes mellitus at year 20. This finding of the association between lung function and diabetes mellitus risk has been previously reported with many potential mechanisms being proposed ranging from the impact of lung function on decreased physical activity influencing diabetes mellitus risk to activation of common inflammatory pathways which impact both lung health and insulin sensitivity. 20, 50, 51 Our findings imply that the association between lung function in young adulthood with hypertension, diabetes mellitus, and eventually heart failure and cerebrovascular events may lie more along metabolic pathways that impact vascular compliance. Indeed, several studies in older populations have shown an inverse cross-sectional relationship between lung function and markers of arterial compliance, but whether this is a consequence of low peak lung function or accelerated decline in lung function cannot be discerned in these studies.
2,52-55 We have previously noted in the CARDIA study that different patterns of lung function decline from young adulthood are associated with distinct echocardiographic phenotypes in middle age. When FVC and FEV 1 declined in conjunction with one another leaving a preserved FEV 1 /FVC ratio, a pattern that could be a precursor of restrictive lung physiology, the echocardiographic phenotype was hypertrophy and diastolic dysfunction. When FEV 1 declined with a preserved FVC such that the FEV 1 /FVC ratio dropped, a pattern that could be a precursor to obstructive lung physiology, the echocardiographic phenotype was an underfilled left heart with low output state. 41 In the current article, we found similarly that baseline FVC is associated heart failure events while FEV 1 was not and that FEV 1 was associated with CIMT while FVC was not. Although, in general, FVC and FEV 1 measurements are highly correlated, this does raise an interesting question related to whether a pattern of airway abnormalities (diminished FEV 1 ) versus overall lung restriction (diminished FVC), which is established in young adulthood, influences future cardiovascular phenotypes. Prior work from our group has pointed toward systemic inflammation being associated with lung restriction and sustained inflammation is associated with heart failure, in particular heart failure with preserved ejection fraction. 21, 56 One could speculate that the diminished FEV 1 out of proportion to FVC (the airway abnormality pattern) further implies something beyond just a generalized systemic inflammatory response that increases risk of carotid atherosclerotic disease. This idea is reinforced by the fact that there is a well-established association between COPD (the classic established airway disease) and atherosclerosis. 4 
Study Strengths and Limitations
A notable strength is that the CARDIA cohort provides a unique opportunity to study heart lung interactions since it includes multiple measurements of lung function in early adulthood in a well-characterized group with long-term reporting of CVD events. This allows for prospectively studying the relationship of lung health to the development of CVD rather than focusing on the relationship of the heart and lung after disease is established, thus avoiding the potential for reverse causation bias. A limitation inherent to any large epidemiologic study is the inability to study mechanistic pathways of disease. Although our findings related to cardiovascular risk factors, CAC, and CIMT in relation to lung function are intriguing, suggesting that lung health influences cardiovascular events independent of coronary artery disease, without a prospective study specifically designed to study pathways of disease evolution, the true mechanistic link between lung health and cardiovascular risk remains to be determined.
Conclusions
Lower lung function in early adulthood is independently associated with cardiovascular events into middle age. We show that it is not only lung disease in young adulthood (defined as FEV 1 or FVC <80% predicted) that is associated with lung and cardiac comorbidities later in life, rather the full continuum of lung health measured when individuals are in their mid-20s is associated with cardiovascular events over 29 years of follow-up. This association is noted at an age when lung function measurements are within the normal ranges and occurs independent of known cardiovascular risk factors and atherosclerotic heart disease. Our findings add to the growing body of evidence exploring the importance of peak lung health attained in young adulthood on the coevolution of heart and lung disease across the adult lifespan. A greater understanding of the physiologic links between measurements of lung function and cardiovascular health across the lifespan is needed to define preventive health strategies focused on the concurrent evolution of common cardiovascular and respiratory conditions.
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